| Identification | Back Directory | [Name]
4-Iodo Suberoylanilide HydroxaMic Acid | [CAS]
1219807-87-0 | [Synonyms]
4-iodo-SAHA
4-Iodo Suberoylanilide HydroxaMic Acid
N1-Hydroxy-N8-(4-iodophenyl)octanediaMide | [Molecular Formula]
C14H19IN2O3 | [MOL File]
1219807-87-0.mol | [Molecular Weight]
390.22 |
| Chemical Properties | Back Directory | [density ]
1.579±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; insoluble in EtOH; ≥1.67 mg/mL in DMSO | [form ]
A crystalline solid | [pka]
9.48±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
A SAHA derivative with antiproliferative activity in several human cancer cell lines. | [Uses]
A SAHA derivative with antiproliferative activity in several human cancer cell lines. Antitumor agent. | [Biological Activity]
4-iodo-saha is a hydrophobic derivative of saha, the class i and class ii histone deacetylase (hdac) inhibitor [1].the reversible acetylation of lysine residues in histone plays an important role in transcriptional activation and repression. the regulation of these post-translational modifications is balanced by histone acetyltransferase (hat) and histone deacetylase (hdac) activities. hdacs are also involved in reversible acetylation of non-histone proteins [1].4-iodo-saha is a histone deacetylase (hdac) inhibitor. in skbr3-breast-derived cell line, 4-iodo-saha inhibited cell proliferation with ec50 value of 1.1 μm. in ht29 colon-derived cell line, leukemia-derived u937 tumor cell line, ja16, hl60 and k562 cell lines, 4-iodo-saha inhibited cell proliferation with ec50 values of 0.95, 0.12, 0.24, 0.85 and 1.3 μm, respectively. 4-iodo-saha is 10-fold more potent as an inhibitor of u937 leukemia cell proliferation compared to saha (0.12 μm versus 1.2 μm). in skbr3 cells, 4-iodo-saha reduced acetylated h4 and p21 levels [1]. | [in vivo]
4-Iodo-SAHA (1k) (50 mg/kg; p.o. five times a week for two weeks) compares to SAHA-treated and control mice with similar toxicity[1]. | Animal Model: | 8-week-old fvb mice[1] | | Dosage: | 50 mg/kg | | Administration: | Oral gavage; 50 mg/kg five times per week; for 2 weeks | | Result: | Compared to both SAHA-treated and control mice with similar body weights and hematological counts. |
| [storage]
Store at -20°C | [References]
[1]. salmi-smail c, fabre a, dequiedt f, et al. modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. j med chem. 2010 apr 22;53(8):3038-47. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|